Response to "erlotinib and gastric Acid-reducing agents: a combination to avoid or to support?"

Clin Pharmacol Ther. 2014 Dec;96(6):659. doi: 10.1038/clpt.2014.192. Epub 2014 Sep 23.

Authors

L Zhang¹, S C Lee¹, H Zhao¹, F Wu², L Zhang¹

Affiliations

¹ Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.
² 1] Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA [2] Oak Ridge Institute for Science and Education, Oak Ridge, Tennessee, USA.

PMID: 25247623
DOI: 10.1038/clpt.2014.192

No abstract available

Publication types

Letter
Comment

MeSH terms

Animals
Drug Design*
Drug Discovery / trends*
Drug Interactions / physiology*
Drug Labeling / trends*
Humans
Pharmaceutical Preparations / metabolism*

Substances

Pharmaceutical Preparations